KIT and gastrointestinal stromal tumor: Tyrosine kinase inhibitors (TKI), such as imatinib, inhibit KIT-downstream PI3K and MAPK signaling and consequently impair the viability of GIST cells in which KIT signaling is constitutively activated [12].